Lyme disease vaccine (GlaxoSmithKline/Valneva)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLyme disease vaccine (GlaxoSmithKline/Valneva)
Drug Alias NameBorrelia vaccine - GlaxoSmithKline/ValnevaLyme borreliosis vaccine - GlaxoSmithKline/ValnevaVLA-15PF-07307405
ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLyme DiseaseLyme Neuroborreliosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcValneva Austria Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncValneva Austria Gmbh
Inactive CompaniesN/A
Active IndicationsLyme Disease
Inactive IndicationsLyme Neuroborreliosis

Other Information

ATC CodeN/A
Related LinksN/A